Shareholder letter...
Shareholder letter...
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
Feb 1, 2024 • 11:00 EST | Read More
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
Dec 6, 2023 • 9:30 EST | Read More